两种剂量他莫昔芬（诺瓦得士）治疗绝经后晚期乳腺癌女性的比较：每日两次，每次10毫克与每日两次，每次20毫克。
A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd.
作者信息
Bratherton D G, Brown C H, Buchanan R, Hall V, Kingsley Pillers E M, Wheeler T K, Williams C J
出版信息
Br J Cancer. 1984 Aug;50(2):199-205. doi: 10.1038/bjc.1984.163.
Abstract
In a comparative double-blind trial involving 263 postmenopausal women with advanced breast cancer treated with tamoxifen, the mean objective tumour response rate and duration was 32% and 15 months respectively. No significant difference was found in clinical response and adverse effects between those randomised to 10 mg and those to 20 mg twice daily. Although the mean serum concentration of tamoxifen in the 20 mg bd group was significantly higher no correlation between serum level and clinical benefit was demonstrated.
摘要
在一项涉及263名接受他莫昔芬治疗的绝经后晚期乳腺癌女性的双盲对照试验中，客观肿瘤缓解率均值和缓解持续时间分别为32%和15个月。随机分为每日两次服用10毫克组和20毫克组的患者，在临床反应和不良反应方面未发现显著差异。虽然每日两次服用20毫克组的他莫昔芬血清浓度均值显著更高，但未证明血清水平与临床获益之间存在相关性。
相似文献
1
A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd.两种剂量他莫昔芬（诺瓦得士）治疗绝经后晚期乳腺癌女性的比较：每日两次，每次10毫克与每日两次，每次20毫克。
Br J Cancer. 1984 Aug;50(2):199-205. doi: 10.1038/bjc.1984.163.
2
Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer.他莫昔芬与氨鲁米特及他莫昔芬联合氨鲁米特治疗绝经后晚期乳腺癌的随机试验
Oncology. 1988;45(5):350-3. doi: 10.1159/000226639.
3
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.阿那曲唑与他莫昔芬用于接受肿块切除术加放疗的绝经后原位导管癌女性患者的疗效比较（NSABP B-35）：一项随机、双盲、3期临床试验。
Lancet. 2016 Feb 27;387(10021):849-56. doi: 10.1016/S0140-6736(15)01168-X. Epub 2015 Dec 11.
4
5
A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen.一项关于二吲哚甲烷对服用他莫昔芬患者乳腺癌生物标志物调节作用的随机、安慰剂对照试验。
Breast Cancer Res Treat. 2017 Aug;165(1):97-107. doi: 10.1007/s10549-017-4292-7. Epub 2017 May 30.
6
Tamoxifen (Nolvadex) for premenopausal patients with advanced breast cancer.
Breast Cancer Res Treat. 1984;4(1):45-8. doi: 10.1007/BF01806987.
7
The tamoxifen trial - a double-blind comparison with stilboestrol in postmenopausal women with advanced breast cancer.
Eur J Cancer (1965). 1980;Suppl 1:83-8.
8
9
10
The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial.替勃龙对乳腺癌术后接受他莫昔芬治疗的绝经后女性的影响：一项随机、双盲、安慰剂对照试验。
BJOG. 2005 Feb;112(2):228-33. doi: 10.1111/j.1471-0528.2004.00309.x.
引用本文的文献
1
Impact of Irradiation on the Pharmacokinetics and Biotransformation of Tamoxifen.辐射对他莫昔芬药代动力学和生物转化的影响。
Front Oncol. 2022 Feb 17;12:833108. doi: 10.3389/fonc.2022.833108. eCollection 2022.
2
Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer.他莫昔芬精准给药的依西美坦血药浓度监测：激素敏感型乳腺癌患者可行。
Clin Pharmacokinet. 2022 Apr;61(4):527-537. doi: 10.1007/s40262-021-01077-z. Epub 2021 Nov 17.
3
Phase 1 study of Z-endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumors.Z-恩杂他胺在晚期妇科、硬纤维瘤及激素受体阳性实体瘤患者中的1期研究。
Oncotarget. 2021 Feb 16;12(4):268-277. doi: 10.18632/oncotarget.27887.
4
Current Medical Treatment of Patients with Non-Colorectal Liver Metastases: Primary Tumor Breast Cancer.非结直肠癌肝转移患者的当前医学治疗：原发性肿瘤为乳腺癌
Viszeralmedizin. 2015 Dec;31(6):424-32. doi: 10.1159/000441961. Epub 2015 Dec 3.
5
Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen.药物遗传学对他莫昔芬药代动力学和药效学的影响。
Clin Pharmacokinet. 2015 Aug;54(8):797-810. doi: 10.1007/s40262-015-0273-3.
6
Physiologically Based Pharmacokinetic Modeling of Tamoxifen and its Metabolites in Women of Different CYP2D6 Phenotypes Provides New Insight into the Tamoxifen Mass Balance.不同CYP2D6表型女性中他莫昔芬及其代谢物的生理药代动力学建模为他莫昔芬质量平衡提供了新的见解。
Front Pharmacol. 2012 May 21;3:92. doi: 10.3389/fphar.2012.00092. eCollection 2012.
7
In vitro metabolic interactions between black cohosh (Cimicifuga racemosa) and tamoxifen via inhibition of cytochromes P450 2D6 and 3A4.黑升麻（总状升麻）与他莫昔芬通过抑制细胞色素P450 2D6和3A4的体外代谢相互作用。
Xenobiotica. 2011 Aug 9. doi: 10.3109/00498254.2011.603385.
8
Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: a case report and review of the literature.抗雌激素疗法治疗复发性卵巢癌获28个月疾病稳定：一例病例报告及文献综述
Arch Oncol. 2010;18(1-2):32-35. doi: 10.2298/AOO1002032K.
9
Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.基因指导的他莫昔芬剂量增加了 CYP2D6 代谢降低的女性中活性代谢物的暴露：一项多中心研究。
J Clin Oncol. 2011 Aug 20;29(24):3232-9. doi: 10.1200/JCO.2010.31.4427. Epub 2011 Jul 18.
10
CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.CYP2D6 基因分型与他莫昔芬：个体化医学探索中尚未完成的篇章。
Semin Oncol. 2011 Apr;38(2):263-73. doi: 10.1053/j.seminoncol.2011.01.002.
本文引用的文献
1
Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers.他莫昔芬在正常志愿者体内的代谢及药代动力学研究。
Cancer Treat Rep. 1980 Jun-Jul;64(6-7):761-4.
2
Measurement of tamoxifen in serum by thin-layer densitometry.
J Endocrinol. 1980 Jan;84(1):35-42. doi: 10.1677/joe.0.0840035.
3
Chemotherapy and tamoxifen for breast cancer.
N Engl J Med. 1981 Oct 22;305(17):1014-5. doi: 10.1056/NEJM198110223051713.
4
Trial of tamoxifen at a dose of 40 mg daily after disease progression during tamoxifen therapy at a dose of 20 mg daily.
Cancer Treat Rep. 1982 Jun;66(6):1445-6.
5
Tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal patients with advanced breast cancer: a randomized trial.
Cancer. 1980 Feb 15;45(4):735-41. doi: 10.1002/1097-0142(19800215)45:4<735::aid-cncr2820450421>3.0.co;2-s.
6
Antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: effects on ovarian function.抗雌激素诱导IV期绝经前乳腺癌女性缓解：对卵巢功能的影响
Cancer Treat Rep. 1980 Jun-Jul;64(6-7):779-85.
7
Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels.乳腺癌的抗雌激素治疗：两种剂量水平他莫昔芬的试验
Br Med J. 1973 Jan 6;1(5844):13-4. doi: 10.1136/bmj.1.5844.13.
8
Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland.晚期乳腺癌治疗反应评估：瑞士日内瓦国际抗癌联盟临床肿瘤学项目。
Cancer. 1977 Mar;39(3):1289-94. doi: 10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f.
9
[Anti-oestrogen treatment of metastasising carcinoma of the breast (author's transl)].[乳腺癌转移癌的抗雌激素治疗（作者译）]
Dtsch Med Wochenschr. 1977 May 13;102(19):713-6. doi: 10.1055/s-0028-1104958.
10
Phase II study of tamoxifen: report of 74 patients with stage IV breast cancer.他莫昔芬的II期研究：74例IV期乳腺癌患者的报告。
Cancer Treat Rep. 1976 Oct;60(10):1431-5.
Zotero 插件